CN108250269A - A kind of Antigenic Peptide chain group for treating tumour and its application in drug - Google Patents

A kind of Antigenic Peptide chain group for treating tumour and its application in drug Download PDF

Info

Publication number
CN108250269A
CN108250269A CN201810284756.1A CN201810284756A CN108250269A CN 108250269 A CN108250269 A CN 108250269A CN 201810284756 A CN201810284756 A CN 201810284756A CN 108250269 A CN108250269 A CN 108250269A
Authority
CN
China
Prior art keywords
artificial sequence
prt
val gly
val
ala arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201810284756.1A
Other languages
Chinese (zh)
Inventor
刘玉强
霍冲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Hengjia Biotechnology Development Co Ltd
Original Assignee
Tianjin Hengjia Biotechnology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hengjia Biotechnology Development Co Ltd filed Critical Tianjin Hengjia Biotechnology Development Co Ltd
Priority to CN201810284756.1A priority Critical patent/CN108250269A/en
Publication of CN108250269A publication Critical patent/CN108250269A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The invention discloses a kind of Antigenic Peptide chain group for the treatment of tumour individuation biological immune and its application in drug, the Antigenic Peptide chain group of the treatment tumour includes SEQ ID No：The combination of any one or at least two amino acid sequences in 1 95.The Antigenic Peptide chain group of the present invention can induce the blastomogenic Dendritic Cells of production, antigenic information thus can be presented to T cell as the Dendritic Cells of antigen presenting cell, so as to interact with T cell, T cell is made to generate specific killing tumour cell, plays the role of killing tumor cell.

Description

A kind of Antigenic Peptide chain group for treating tumour and its application in drug
Technical field
It is more particularly to a kind of for tumour individuation biology the invention belongs to malignant tumour biological immune technical field of pharmaceuticals The Antigenic Peptide chain group of immunization therapy and its application in drug.
Background technology
At present, global Cancer Mortality rises increasingly, and the death rate is high, poor prognosis.National Cancer Center whole nation tumour Study on prevention office exists《International journal of cancer》Largest In China scale cancer Survival data Macro or mass analysis data are issued to show, in 5 years survival rates of state's cancer are 30.9%, far below developed country's level；The survival rate of rural patient is only City patient's simultaneously Half.In developed country, prostate cancer, breast cancer occupy the majority, and in China, the cancers such as lung cancer, gastric cancer, liver cancer are more common, hair Sick rate and the highest cancer of the death rate are lung cancer.The traditional therapies therapeutic effect such as operation, chemotherapy, radiotherapy is limited, patient 5 years Survival rate is still relatively low；Especially eliminating side effect of radiotherapy and chemotherapy to is big, and patients ' life quality is poor, and survival rate is low.
Biological immune treatment is the new treatment side of future therapeutic tumour by body immune system killing tumor cell Method has been increasingly becoming the hot spot for the treatment of tumour.The method of the tumour of biological immune treatment at present is more, thin including common CIK Born of the same parents' immunization therapy, DC medications treatment etc., but its therapeutic effect is not notable, and survival is not improved significantly.Separately have With the immunocyte medication that not mutated tumour high-expression albumen stimulates, research has anti tumor immune response, but since its is non-specific Property expression, no doubt with the presence of side reaction, including eye-blurred, Hearing, fash etc..
Invention content
The object of the present invention is to provide a kind of Antigenic Peptide chain group for the treatment of tumour individuation biological immune and its in medicine Application in object, Antigenic Peptide chain group of the invention can induce the blastomogenic Dendritic Cells of production, thus as antigen presenting cell Dendritic Cells antigenic information can be presented to T cell, so as to T cell interact, make T cell generate specific killing Tumour cell plays the role of killing tumor cell.
For this purpose, technical solution of the present invention is as follows：
In a first aspect, the present invention provides a kind of Antigenic Peptide chain group for treating tumour, the Antigenic Peptide chain group of the treatment tumour Including SEQ ID No：The combination of any one or at least two amino acid sequences in 1-95, such as can be SEQ ID No： Any one in 1-95, it is two arbitrary, three arbitrary, four arbitrary, it is arbitrary five until arbitrary 92 or all 95 Combination, since the limitation of length is no longer all enumerated herein.Particular sequence is as shown in table 1：
The Antigenic Peptide chain group of 1 present invention of table
Second aspect, the present invention provide a kind of pharmaceutical composition, and described pharmaceutical composition is included as described in relation to the first aspect SEQ ID No：Any one in 1-95 or at least two amino acid sequences.
Preferably, described pharmaceutical composition is aqueous suspension, solution or solid state.
Preferably, the solid state is uncoated or coated tablet form, such as pill, gel capsule, capsule or powder End etc..
If described pharmaceutical composition is in drying regime, it can for example form sediment with one or more inert diluents The mixing such as powder, cellulose, sucrose, lactose or silica.It can also include other substances in the dry state, such as a kind of Or a variety of lubricants such as magnesium stearate or talcum powder, colorant, coating (sugar coated tablet) or varnish.If the drug of the present invention Composition is liquid form, then it can include containing inert diluent such as water, ethyl alcohol, glycerine, vegetable oil or atoleine Pharmaceutical solution, suspension, emulsion, syrup and elixir.Described pharmaceutical composition can also be included in addition to diluent Other liquid substances, such as wetting agent, sweetener, thickener, flavoring agent or stabilizer product.
Preferably, the auxiliary material pharmaceutically received is further included.
Preferably, the auxiliary material is any one in excipient, diluent, carrier, flavoring agent, adhesive and filler Or at least two combination, such as can be excipient, carrier and diluent, flavoring agent, adhesive and filler or dilution Agent, the combination of carrier, flavoring agent, adhesive and filler, due to the limitation of length, the form of all combinations no longer arranges one by one It lifts.
The third aspect, the Antigenic Peptide chain group that the present invention provides treatment tumour as described in relation to the first aspect are preparing treating cancer Pharmaceutical composition in application.The cancer is the cancer (i.e. entity malignant tumour) of any kind, because the present invention Antigenic Peptide chain group can induce the Dendritic Cells for generating tumour-specific, thus as the Dendritic Cells energy of antigen presenting cell Antigenic information is presented to T cell, so as to interact with T cell, T cell is made to generate specific killing tumour cell, so as to Play the role of killing tumor cell.
In the present invention, the cancer is preferably lung cancer, breast cancer, oophoroma, prostate cancer, melanoma, brain tumor, food Pipe cancer, gastric cancer, liver cancer, cancer of pancreas, colorectal cancer, kidney, cutaneum carcinoma, spongioblastoma, neuroblastoma, sarcoma, Embryonal-cell lipoma, osteochondroma, osteoma, osteosarcoma, seminoma, orchioncus, uterine cancer, H/N tumors, multiple marrow Knurl, malignant lymphoma, polycythemia vera, leukaemia, thyroid tumors, tumor of ureter, tumor of bladder, gallbladder cancer, In cholangiocarcinoma, chorioepithelioma or pediatric tumors any one or at least two combination.In addition, described pharmaceutical composition It can also be with another or at least two anti-cancer agent in conjunction applications, such as arimedex (Letrozole and/or Anastrozole) Deng.
Described pharmaceutical composition may be utilized independently or is used in combination in given treatment with other drugs or with putting Penetrate therapy or operation joint.Specifically used method is：
(1) internal stimulus method：
The Antigenic Peptide chain group of the treatment tumour is dissolved in pH value as in 7.4PBS (Hyclone) solution, concentration is adjusted to Covering 5%Aldara cream (iNova Pharmaceuticals after 200ug are subcutaneously injected in 2.5mg/ml, each upper arm Australia Pty Ltd.), once a week, 12 weeks are a cycle.
(2) stimulated in vitro method：
0th day：
(1) monocyte point is carried out using COBE Spectra blood analysis systems (Caridian BCT, the Inc. U.S.) From acquisition filter blood volume 2500-3500ml；(2) preparation 1LDC-CM culture solutions, 500mlX2 parts；(3) by cell from 4 centrifuge tubes It is transferred in 500ml centrifuge tubes, and rinses former centrifuge tube with 10mlDC-CM, and be transferred to 500ml centrifuge tubes, cover, mixing；(4) With 25ml suction pipes, add 15mlDC-CM to each culture bottle；(5) concentration for adding in IL-4 and GM-CSF is all 1000IU/ml； (6) dilute IL-4, with 1%HAS inside PBS to 1000IU/ml.
6th day：The ripe mixed liquor of addition
(7) with 1%HSA-PBS dilutions IL-1 β, INF- α, IL-6 to 25ug/ml；(8) final concentration：IL-1β10ng/ml、 INF-α10ng/ml、IL-6 15ng/ml；(9) the diluting cells factor is in 44mlDC-CM, until last volume 50ml；(10) with nothing Bacterium suction pipe inhales 1ml and contains the DC-CM of cell factor to each culture bottle；(11) culture bottle be put into incubator (37 DEG C, 5% CO2；± 10 DEG C, ± 0.5%CO2)。
The 7-8 days：Prepare peptide chain pulse culture solution (PPM)
(12) amount of the PPM needed is calculated：The amount for the PPM that culture bottle quantity X30ml+300ml=needs；It (13) will culture Bottle takes out from incubator, and bottle inner cell is transferred to 500ml sterile centrifugation tubes；(14) culture bottle is rinsed with 30mlPPM, and punching Washing lotion is transferred to 500ml centrifuge tubes；(15) all supernatants are shifted with 2ml suction pipes, and cell is resuspended with 25mlPPM, by harvest Harvest pipe DC cells and flush pipe DC cells are merged into same pipe, indicate：DC cell pipes；(16) one group that 1 pipe freezes is taken out Body specific mutations peptide chain dissolves peptide chain with DC-PPM；(17) add peptide chain to DC pipes, a concentration of 5ug/ml；(18) after pine lid Be put into incubator (37 DEG C, 5%CO2；± 10 DEG C, ± 0.5%CO2), per 30min, taking-up incubator, mixing, total time 1.5 are small When；(19) the DC cells that 0.2ml is taken to be resuspended, are transferred in 12X75mm pipes, carry out endotoxin check and evaluation；(20) reduction of speed centrifuges, 1200rpm (309Xg), 7min, room temperature；(21) remove supernatant with 2ml suction pipes；(22) individuation specificity DC cells are harvested, It counts and is dissolved in 1mlPBS solution；(23) tumor-draining lymphode or injection in other.
Compared with prior art, provided by the present invention for the Antigenic Peptide chain group of tumour individuation biological immune treatment at least It has the advantages that：
The present invention provides a kind of Antigenic Peptide chain group for treating tumour and its application in drug, the treatment tumour Antigenic Peptide chain group includes SEQ ID No：The combination of any one or at least two amino acid sequences in 1-95.The present invention's is anti- Former peptide chain group can induce the blastomogenic Dendritic Cells of production, thus the Dendritic Cells as antigen presenting cell can believe antigen Breath is presented to T cell, so as to interact with T cell, T cell is made to generate specific killing tumour cell, plays killing tumour The effect of cell.After medication at least 6 weeks, it can significantly observe that tumour largely disappears by instrument, density is thin out, and variation is apparent； Incidence of side effects is small, less to the injury of patient.
Description of the drawings
Fig. 1 is HLA*A3101-HVKITDFGR Tetramer colored graphs before and after 1 medication of embodiment；
Fig. 2 is the tumour CT scan figure before and after 1 medication of embodiment；
Fig. 3 is the tumour CT scan figure before and after 2 medication of embodiment.
Specific embodiment
Below in conjunction with the accompanying drawings and specific embodiment the present invention is described further, but following embodiments are absolutely not to this hair It is bright to have any restrictions.
Embodiment 1
Patient A, female, 49 years old.Lung gland, hepatic metastases, clinical IV phases are in progress after vinorelbine list medicine chemotherapy 3 times, diagnosis of hepatic metastases It is in progress after chemoembolization and the treatment of I125 seeds implanted, the molecular targeted medicine drug resistances of KRAS.The multiple transfer of intrapulmonary, hepatic metastases, pleura Transfer, Bone tumour, Coeliac lymphadenectomy.Pulmonary lesions tissue biopsy is taken, carries out full extron sequencing and the inspection of HLA typing chips After survey, patient carries KRAS p.G12R mutation, and HLA partings are HLA-A：A*2403A*6501；HLA-B:B*1517B*3201； HLA-C：C*0303C*0712；HLA-DQB1：DQB1*0158DQB1*1121；HLA-DRB1：DRB1*0301DRB1*0601.
Use the specific tumor antigen peptide chain combined therapy of the present invention, 1 times a week, totally 12 weeks.Detect injections of antigens peptide Spot detection specific C D8+Tetramer+T cells secrete situation and pass through image before and after chain group (hereinafter referred to as " medication ") The tumor size variation of 12 weeks before and after observation medication, as a result as depicted in figs. 1 and 2.Specific peptide chain selection is as follows：SEQ ID No：1.
Fig. 1 be HLA*A3101-HVKITDFGR Tetramer colored graphs, wherein, Fig. 1-A be medication before colored graph, CD8 + Tetramer+T a concentration of 2.76%；Fig. 1-B be 6 weeks after stain chromatic graphs of medication, CD8+Tetramer+T a concentration of 3.52%；Figure 1-C be 12 weeks after stain chromatic graphs of medication, CD8+Tetramer+T a concentration of 4.8%；As can be seen that amount of speckle has from three group pictures Significantly raised variation tendency, illustrates that the ratio (concentration) of tumor-killing cell CD8+Tetramer+T in blood significantly improves.
Fig. 2 is lung tumors CT figures before and after medication, and wherein Fig. 2-A are CT figures before medication, for upper lobe of left lung tumour, the greater 4cm×3cm；Fig. 2-B scheme for CT after medication 12 weeks, it can be seen that tumour disappears substantially, and front and rear variation is apparent.
Show that Antigenic Peptide chain group of the invention can induce the blastomogenic Dendritic Cells of production based on the above results, as anti- Antigenic information can be presented to T cell by original in the Dendritic Cells of delivery cell, be interacted with T cell, generate T cell special Property killing tumor cell, plays the role of killing tumor cell, and with obvious effects.
Embodiment 2
Patient B, female, 65 years old, adenocarcinoma of lung, cervical lymph transfer, pleural effusion, oral Gefitinib drug resistance.It carries out complete outer After aobvious son sequencing and the detection of HLA typing chips, patient carries KRAS p.G12R mutation, and HLA partings are HLA-A：A*0102A* 0301；HLA-B:B*0201B*3001；HLA-C：C*0106C*0106；HLA-DQB1：DQB1*0302DQB1*0230；HLA- DRB1：DRB1*0024DRB1*1122.
Treatment is combined using the Antigenic Peptide chain group of the treatment tumour of the present invention, 1 times a week, totally 12 weeks.Specific choice Peptide chain it is as follows：SEQ ID No：2.
Pretherapy and post-treatment lung tumors size variation situation is as shown in figure 3, as seen from Figure 3, before medication treatment, inferior lobe of right lung is swollen Knurl size 4cm × 3cm (Fig. 3-A)；12 weeks after medication treatment, inferior lobe of right lung tumour disappears (Fig. 3-B) substantially, before tumour is compared with medication It is obviously reduced, density is thin out.This example demonstrates that the Antigenic Peptide chain group of the present invention can induce the blastomogenic Dendritic Cells of production, make Antigenic information can be presented to T cell by the Dendritic Cells for antigen presenting cell, interacted with T cell, generated T cell Specific killing tumour cell plays the role of killing tumor cell, and with obvious effects.
Embodiment 3-95
Embodiment 3-95 takes variety classes, and different degrees of cancer patient carries out full extron sequencing and HLA typing chips After detection, patient is to carry KRAS p.G12R mutation patients, is carried out respectively using the combining form of different Antigenic Peptide chain groups Treatment, once a week, totally 12 weeks.HLA*A3101-HVKITDFGR Tetramer coloration results of embodiment 3-95 and treatment Front and rear lung tumors size variation situation is similar with embodiment 1-2, and due to the limitation of length, it is no longer repeated herein.More than As a result the Antigenic Peptide chain group that the present invention can be explained can induce the blastomogenic Dendritic Cells of production, the tree as antigen presenting cell Antigenic information can be presented to T cell by prominent shape cell, be interacted with T cell, T cell be made to generate specific killing tumour thin Born of the same parents play the role of killing tumor cell, and with obvious effects.
During being treated to embodiment 1-95, with before ELISA detections antigen peptide chain, medication 3 weeks, 7 weeks, 11 weeks Specific IFN-γ secretion situation, concrete outcome are as shown in table 1.
Comparative example 1-10
To comparative example 1-10 (carry out full extron sequencing and HLA typing chips detection after, patient be carry KRAS P.G12R is mutated patient) treated during, before detecting medication with ELISA, medication 3 weeks, 7 weeks, the specific IFN-γ of 11 weeks Secretion situation, concrete outcome is as shown in table 2, and dosage is identical with embodiment 1-95；Wherein, comparative example 1-5 is added without peptide chain.
From table 2 it can be seen that embodiment 1-95,11 weeks after medication, the specific IFN-γ level of T cell secretion has Significantly raised trend, illustrate to have used any one in the Antigenic Peptide chain group of the present invention or its arbitrarily combine and can increase cancer The tumor-killing ability of disease peripheral blood in patients further demonstrates the effect of the present invention.And in comparative example 1-10, IFN-γ is horizontal Also increased before and after medication, it may be possible to the effect of the nutritional ingredient of addition as a result, but all in all concentration increment it is far low In embodiment 1-95, illustrate that it does not increase the tumor-killing ability of peripheral blood in patients or the ability of blood killing tumour is far below Embodiment 1-95 further demonstrates the effect of the present invention.
Table 2IFN- γ secretion statistics lists
Then, the rate of side effects of embodiment 1-95 is counted, the results are shown in Table 2, can from table 2 Go out, used the present invention Antigenic Peptide chain group after, the incidence (i.e. positive rate) of side reaction is relatively low, illustrate its side effect compared with Small, the influence and injury to patient are relatively low.
2 rate of side effects statistical result of table
It should be noted that and understand, the feelings of the spirit and scope of the present invention required by appended claims are not departed from Under condition, various modifications and improvements can be made to the present invention of foregoing detailed description.It is therefore desirable to the model of the technical solution of protection It encloses and is not limited by given any specific exemplary teachings.
Applicant states, made for the present invention further specifically the above content is specific preferred embodiment is combined It is bright, it is impossible to assert that the specific implementation of the present invention is confined to these explanations.For the ordinary skill of the technical field of the invention For personnel, without departing from the inventive concept of the premise, several simple deduction or replace can also be made, should all be considered as category In protection scope of the present invention.
Sequence table
<110>Tianjin Heng Jia biotechnologies Development Co., Ltd
<120>A kind of Antigenic Peptide chain group for treating tumour and its application in drug
<130> 20180401
<160> 95
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 1
Leu Val Val Val Gly Ala Arg
1 5
<210> 2
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 2
Val Val Val Gly Ala Arg Gly
1 5
<210> 3
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 3
Val Val Gly Ala Arg Gly Val
1 5
<210> 4
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 4
Val Gly Ala Arg Gly Val Gly
1 5
<210> 5
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 5
Gly Ala Arg Gly Val Gly Lys
1 5
<210> 6
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 6
Ala Arg Gly Val Gly Lys Ser
1 5
<210> 7
<211> 7
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 7
Arg Gly Val Gly Lys Ser Ala
1 5
<210> 8
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 8
Lys Leu Val Val Val Gly Ala Arg
1 5
<210> 9
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 9
Leu Val Val Val Gly Ala Arg Gly
1 5
<210> 10
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 10
Val Val Val Gly Ala Arg Gly Val
1 5
<210> 11
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 11
Val Val Gly Ala Arg Gly Val Gly
1 5
<210> 12
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 12
Val Gly Ala Arg Gly Val Gly Lys
1 5
<210> 13
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 13
Gly Ala Arg Gly Val Gly Lys Ser
1 5
<210> 14
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 14
Ala Arg Gly Val Gly Lys Ser Ala
1 5
<210> 15
<211> 8
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 15
Arg Gly Val Gly Lys Ser Ala Leu
1 5
<210> 16
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 16
Tyr Lys Leu Val Val Val Gly Ala Arg
1 5
<210> 17
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 17
Lys Leu Val Val Val Gly Ala Arg Gly
1 5
<210> 18
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 18
Leu Val Val Val Gly Ala Arg Gly Val
1 5
<210> 19
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 19
Val Val Val Gly Ala Arg Gly Val Gly
1 5
<210> 20
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 20
Val Val Gly Ala Arg Gly Val Gly Lys
1 5
<210> 21
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 21
Val Gly Ala Arg Gly Val Gly Lys Ser
1 5
<210> 22
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 22
Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5
<210> 23
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 23
Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5
<210> 24
<211> 9
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 24
Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5
<210> 25
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 25
Glu Tyr Lys Leu Val Val Val Gly Ala Arg
1 5 10
<210> 26
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 26
Tyr Lys Leu Val Val Val Gly Ala Arg Gly
1 5 10
<210> 27
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 27
Lys Leu Val Val Val Gly Ala Arg Gly Val
1 5 10
<210> 28
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 28
Leu Val Val Val Gly Ala Arg Gly Val Gly
1 5 10
<210> 29
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 29
Val Val Val Gly Ala Arg Gly Val Gly Lys
1 5 10
<210> 30
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 30
Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10
<210> 31
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 31
Val Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5 10
<210> 32
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 32
Gly Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5 10
<210> 33
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 33
Ala Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5 10
<210> 34
<211> 10
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 34
Arg Gly Val Gly Lys Ser Ala Leu Thr Ile
1 5 10
<210> 35
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 35
Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg
1 5 10
<210> 36
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 36
Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly
1 5 10
<210> 37
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 37
Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val
1 5 10
<210> 38
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 38
Lys Leu Val Val Val Gly Ala Arg Gly Val Gly
1 5 10
<210> 39
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 39
Leu Val Val Val Gly Ala Arg Gly Val Gly Lys
1 5 10
<210> 40
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 40
Val Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10
<210> 41
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 41
Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5 10
<210> 42
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 42
Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5 10
<210> 43
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 43
Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5 10
<210> 44
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 44
Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile
1 5 10
<210> 45
<211> 11
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 45
Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln
1 5 10
<210> 46
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 46
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg
1 5 10
<210> 47
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 47
Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly
1 5 10
<210> 48
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 48
Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val
1 5 10
<210> 49
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 49
Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly
1 5 10
<210> 50
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 50
Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys
1 5 10
<210> 51
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 51
Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10
<210> 52
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 52
Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5 10
<210> 53
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 53
Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5 10
<210> 54
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 54
Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5 10
<210> 55
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 55
Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile
1 5 10
<210> 56
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 56
Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln
1 5 10
<210> 57
<211> 12
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 57
Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu
1 5 10
<210> 58
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 58
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val
1 5 10
<210> 59
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 59
Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly
1 5 10
<210> 60
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 60
Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys
1 5 10
<210> 61
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 61
Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10
<210> 62
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 62
Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5 10
<210> 63
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 63
Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5 10
<210> 64
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 64
Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5 10
<210> 65
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 65
Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile
1 5 10
<210> 66
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 66
Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln
1 5 10
<210> 67
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 67
Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu
1 5 10
<210> 68
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 68
Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile
1 5 10
<210> 69
<211> 14
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 69
Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln
1 5 10
<210> 70
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 70
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly
1 5 10 15
<210> 71
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 71
Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys
1 5 10 15
<210> 72
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 72
Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10 15
<210> 73
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 73
Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5 10 15
<210> 74
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 74
Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5 10 15
<210> 75
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 75
Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5 10 15
<210> 76
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 76
Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile
1 5 10 15
<210> 77
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 77
Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln
1 5 10 15
<210> 78
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 78
Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu
1 5 10 15
<210> 79
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 79
Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile
1 5 10 15
<210> 80
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 80
Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln
1 5 10 15
<210> 81
<211> 15
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 81
Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn
1 5 10 15
<210> 82
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 82
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys
1 5 10 15
<210> 83
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 83
Thr Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser
1 5 10 15
<210> 84
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 84
Glu Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala
1 5 10 15
<210> 85
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 85
Tyr Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu
1 5 10 15
<210> 86
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 86
Lys Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr
1 5 10 15
<210> 87
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 87
Leu Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile
1 5 10 15
<210> 88
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 88
Val Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln
1 5 10 15
<210> 89
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 89
Val Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu
1 5 10 15
<210> 90
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 90
Val Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile
1 5 10 15
<210> 91
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 91
Gly Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln
1 5 10 15
<210> 92
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 92
Ala Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn
1 5 10 15
<210> 93
<211> 16
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 93
Arg Gly Val Gly Lys Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His
1 5 10 15
<210> 94
<211> 17
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 94
Leu Thr Ser Thr Val Gln Leu Ile Met Gln Leu Met Pro Phe Gly Cys
1 5 10 15
Leu
<210> 95
<211> 17
<212> PRT
<213>Artificial sequence (artificial sequence)
<400> 95
Leu Leu Gly Arg Asn Ser Phe Glu Leu Arg Val Cys Ala Cys Pro Gly
1 5 10 15
Arg

Claims (7)

1. a kind of Antigenic Peptide chain group for treating tumour, which is characterized in that the Antigenic Peptide chain group of the treatment tumour includes SEQ ID No：The combination of any one or at least two amino acid sequences in 1-95.
2. a kind of pharmaceutical composition, which is characterized in that described pharmaceutical composition includes SEQ ID No described in claim 1：1- Any one in 95 or at least two amino acid sequences.
3. pharmaceutical composition according to claim 2, which is characterized in that described pharmaceutical composition is aqueous suspension, solution Or solid state.
4. pharmaceutical composition according to claim 3, which is characterized in that the solid state is uncoated or coated tablet Form.
5. according to the pharmaceutical composition described in any one of claim 2-4, which is characterized in that further include pharmaceutically receive it is auxiliary Material.
6. pharmaceutical composition according to claim 5, which is characterized in that the auxiliary material for excipient, diluent, carrier, In flavoring agent, adhesive and filler any one or at least two combination.
7. Antigenic Peptide chain group the answering in the pharmaceutical composition for preparing treating cancer for the treatment of tumour according to claim 1 With.
CN201810284756.1A 2018-04-02 2018-04-02 A kind of Antigenic Peptide chain group for treating tumour and its application in drug Withdrawn CN108250269A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810284756.1A CN108250269A (en) 2018-04-02 2018-04-02 A kind of Antigenic Peptide chain group for treating tumour and its application in drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810284756.1A CN108250269A (en) 2018-04-02 2018-04-02 A kind of Antigenic Peptide chain group for treating tumour and its application in drug

Publications (1)

Publication Number Publication Date
CN108250269A true CN108250269A (en) 2018-07-06

Family

ID=62747908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810284756.1A Withdrawn CN108250269A (en) 2018-04-02 2018-04-02 A kind of Antigenic Peptide chain group for treating tumour and its application in drug

Country Status (1)

Country Link
CN (1) CN108250269A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021170684A1 (en) * 2020-02-24 2021-09-02 Oblique Therapeutics Ab Kras epitopes and antibodies
CN113416241A (en) * 2020-04-09 2021-09-21 北京臻知医学科技有限责任公司 Universal antigen peptide library and kit for inducing tumor specific immune response
CN114085286A (en) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 Tumor neogenesis antigen epitope peptide Pep5 and polymer and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448848A (en) * 2006-03-27 2009-06-03 全球免疫股份有限公司 Ras mutation and compositions and mehods related thereto
WO2016202963A2 (en) * 2015-06-19 2016-12-22 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448848A (en) * 2006-03-27 2009-06-03 全球免疫股份有限公司 Ras mutation and compositions and mehods related thereto
WO2016202963A2 (en) * 2015-06-19 2016-12-22 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
WANG 等: "Human tumor antigens for cancer vaccine development", 《IMMUNOLOGICAL REVIEWS》 *
杨帆 等: "肿瘤抗原肽及CTL杀伤机理的研究进展", 《中国肿瘤》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021170684A1 (en) * 2020-02-24 2021-09-02 Oblique Therapeutics Ab Kras epitopes and antibodies
CN113416241A (en) * 2020-04-09 2021-09-21 北京臻知医学科技有限责任公司 Universal antigen peptide library and kit for inducing tumor specific immune response
CN113416241B (en) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 Universal antigen peptide library and kit for inducing tumor specific immune response
CN114085286A (en) * 2021-10-15 2022-02-25 北京臻知医学科技有限责任公司 Tumor neogenesis antigen epitope peptide Pep5 and polymer and application thereof

Similar Documents

Publication Publication Date Title
US8933038B2 (en) Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
CN104312974B (en) The method of activation of helper t cell and composition for this method
CN104922656B (en) Immune inducing agent
US11154571B2 (en) Exosomes sourced from granulocytic myeloid-derived suppressor cells and application thereof
CN110248645A (en) The novel anticancer agent based on allochthon
CN108250269A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
Ke et al. The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo
CN108601811A (en) SLC45A2 peptides for immunization therapy
CN108440646A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108440647A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN104262459B (en) Acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide, and vaccine and pharmaceutical application of acute monocytic leukemia-associated antigen MLAA-34 epitope polypeptide
CN109152813A (en) As target and for the new type of peptides of gallbladder cancer and cholangiocarcinoma and other cancer immunotherapies, peptide combinations
CN108484731A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN109803981A (en) New type of peptides and bracket for Head and neck squamous cell carcinoma and other cancer immunotherapies
CN108250268A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108218961A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108047308A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108440648A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108218959A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108484730A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108440650A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108484732A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108752424A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108715603A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug
CN108440649A (en) A kind of Antigenic Peptide chain group for treating tumour and its application in drug

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20180706